Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
dual FAAH/MAGL inhibitor
JZL195 is a selective and efficacious dual FAAH/MAGL inhibitor with IC50 of 13 nM and 19 nM for mouse brain FAAH and MAGL respectively.- Lakhan S Khara, .et al. , J Exp Biol, 2022, May 1;225(9):jeb244146 PMID: 35438163
- Md Shah Sufian, .et al. , J Exp Biol, 2021, 21 JUNE PMID: 34435626
-
FAAH inhibitor
URB597 is a relatively selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH).- Lakhan S Khara, .et al. , J Exp Biol, 2022, May 1;225(9):jeb244146 PMID: 35438163
- Md Shah Sufian, .et al. , J Exp Biol, 2021, 21 JUNE PMID: 34435626
- Toshihiko Tsutsumi, .et al. , Biochim Biophys Acta Mol Cell Biol Lipids, 2020, Sep;1865(9):158761 PMID: 32629025
-
FAAH inhibitor
JNJ 1661010 is a selective and reversible inhibitor of fatty acid amide hydrolase (FAAH) (IC50 = 12nM). -
FAAH inhibitor
LY 2183240 acts both as a potent inhibitor of the reuptake of the endocannabinoid anandamide, and as an inhibitor of fatty acid amide hydrolase (FAAH), the primary enzyme responsible for degrading anandamide. -
FAAH inhibitor
BIA10-2474 is a long-acting reversible inhibitor of fatty acid amide hydrolase (FAAH) . -
FAAH inhibitor
JNJ-42165279 is a potent and selective fatty acid amide hydrolase (FAAH) inhibitor. -
FAAH inhibitor
FAAH-IN-2 (O-Desmorpholinopropyl Gefitinib) is a potent FAAH(fatty acid amide hydrolase) inhibitor extracted from Patent WO/2008/100977A2. -
FAAH inhibitor
PF-04457845 is a potent and exquisitely selective inhibitor of FAAH, with an IC50 of 7.2 nM, and both analgesic and antiinflammatory effects in animal studies comparable to naproxen. -
FAAH Inhibitor
N-Benzyllinolenamide is a natural macamide derived from Lepidium meyenii and acts as an inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 value of 41.8 μM. This compound is valuable for studying the modulation of endocannabinoid signaling pathways and investigating the role of FAAH in various physiological processes. Its ability to inhibit FAAH makes it a useful tool in research related to pain management, inflammation, and neuroprotection. -
FAAH Inhibitor
SA72 is a highly selective inhibitor of fatty acid amide hydrolase (FAAH), an enzyme crucial for the degradation of endocannabinoids. By inhibiting FAAH, SA72 modulates endocannabinoid levels, leading to potential therapeutic effects in pain management and inflammation. This compound serves as a valuable tool in research aimed at understanding the endocannabinoid system and its role in various physiological processes. -
FAAH inhibitor
FAAH inhibitor 1 (Benzothiazole analog 3) is a potent fatty acid amide hydrolase (FAAH) inhibitor with an IC50 of 18??8 nM. -
FAAH/MAGL Inhibitor
1-Monomyristin serves as a dual inhibitor of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), with IC50 values of 18 μM and 32 μM, respectively. It effectively inhibits the hydrolysis of 2-oleoylglycerol via MAGL, exhibiting antibacterial and antifungal activities against pathogens such as Staphylococcus aureus, Aggregatibacter actinomycetemcomitans, and Candida albicans. Additionally, 1-Monomyristin demonstrates lethality to brine shrimp and shows marginal cytotoxicity against prostate cancer cells. This reagent is suitable for research focused on bacterial and fungal infections, as well as various cancer types, including renal cancer, prostate adenocarcinoma, and pancreatic cancer. -
FAAH Inhibitor
Macamide B is a selective inhibitor of fatty acid amide hydrolase (FAAH), derived from the plant Lepidium meyenii. This compound has been shown to enhance levels of endocannabinoids by inhibiting their degradation, thereby playing a crucial role in modulating pain and inflammation. Macamide B is primarily utilized in research focused on pain management, neuroprotection, and the therapeutic potential of endocannabinoids in various physiological processes. -
CB/FAAH Inhibitor
Isopropyl dodec-11-enylfluorophosphonate (IDEFP) is a potent inhibitor of the central cannabinoid receptor (CB1) and fatty acid amide hydrolase (FAAH), exhibiting similar inhibitory activities with IC50 values around 2 nM. It serves as a valuable tool for investigating cannabinoid signaling pathways and lipid metabolism in various biological contexts. Researchers utilize IDEFP to explore the therapeutic potential of modulating endocannabinoid systems in pain, inflammation, and neuroprotection studies. -
CB2R Agonist/FAAH Inhibitor
CB2R/FAAH modulator-1 is a potent full agonist of the cannabinoid type 2 receptor (CB2R), exhibiting a binding affinity with a Ki of 14.8 nM for CB2R and 241.3 nM for CB1R. This compound also serves as an inhibitor of fatty acid amide hydrolase (FAAH), demonstrating an IC50 of 4 μM. CB2R/FAAH modulator-1 is effective in modulating cytokine production by decreasing pro-inflammatory cytokines while enhancing anti-inflammatory cytokine levels, making it valuable for research in inflammation and pain modulation. -
FAAH/COX Inhibitor
Carpro-AM1 is a dual-acting inhibitor targeting fatty acid amide hydrolase (FAAH) and selectively inhibiting cyclooxygenase (COX) enzymes. This compound exhibits an IC50 value of 94 nM for FAAH, demonstrating significant biological activity in regulating endocannabinoid signaling. Carpro-AM1 is suited for research applications focusing on pain management, inflammation, and the modulation of the endocannabinoid system. -
FAAH/sEH Inhibitor
Dual FAAH/sEH-IN-1 is a potent dual inhibitor of soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH), exhibiting IC50 values of 9.6 nM and 7 nM, respectively. This compound demonstrates significant antinociceptive effects during the inflammatory phase, making it a valuable tool for studying pain pathways and potential therapeutic interventions in pain management. Its ability to modulate lipid signaling pathways positions it for applications in neurobiology and pharmacology research. -
FAAH Inhibitor
ST4070 is a potent and selective reversible inhibitor of fatty acid amide hydrolase (FAAH). This compound elevates endocannabinoid levels in the brain, effectively counteracting neuropathic pain in preclinical animal models. Furthermore, ST4070 modulates endocannabinoid tone in brain regions associated with emotional regulation and produces significant anxiolytic-like effects in rodents. It is a valuable tool for research into neuropathic pain and anxiety disorders. -
FAAH Inhibitor
URB524 is an irreversible inhibitor of fatty acid amide hydrolase (FAAH) through the aminoformylation of Ser241. This compound demonstrates significant analgesic, antidepressant, and anxiolytic properties, making it valuable for research in pain management, mood disorders, and anxiety studies. Its ability to modulate endocannabinoid levels positions URB524 as a crucial tool in the investigation of cannabinoid-related pathways and therapeutics. -
FAAH Inhibitor
URB937 is a potent and peripherally restricted inhibitor of fatty acid amide hydrolase (FAAH), with an IC50 value of 26.8 nM. This compound effectively elevates anandamide levels, making it valuable for studies on endocannabinoid signaling. Due to its inability to cross the blood-brain barrier, URB937 is particularly useful for investigating peripheral FAAH activity and its implications in various biological processes and therapeutic applications. -
FAAH Inhibitor
TC-F2 is a reversible non-covalent inhibitor of fatty acid amide hydrolase (FAAH), exhibiting an IC50 of 28 nM. By modulating FAAH activity, TC-F2 is pertinent for research focused on various human diseases, including cancer, pain, inflammation, as well as neurological, metabolic, and cardiovascular disorders. This compound provides a valuable tool for investigating the therapeutic potential of FAAH inhibition in these areas. -
FAAH/MAGL Inhibitor
FAAH/MAGL-IN-5 is a potent inhibitor of both fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), exhibiting equipotent inhibitory activity with an IC50 of 1.2 nM. This dual inhibition results in enhanced endocannabinoid levels, contributing to neuroprotective effects. FAAH/MAGL-IN-5 is valuable in research applications focused on pain management, neurodegenerative disorders, and the modulation of the endocannabinoid system. -
FAAH/MAG Inhibitor
AKU-005 is a dual inhibitor of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), exhibiting IC50 values of 63 nM and 389 nM for rat and human FAAH, respectively. This compound demonstrates significant potential in the study of trigeminal hyperalgesia and related pain pathways, making it a valuable tool for researchers investigating endocannabinoid signaling and pain modulation mechanisms. -
FAAH Inhibitor
AM 374 is a potent inhibitor of fatty acid amide hydrolase (FAAH), demonstrating an IC50 value of 13 nM for amidase activity inhibition. This compound is utilized in research focused on neurological diseases, contributing to the understanding of endocannabinoid signaling pathways and their therapeutic potential in various conditions. -
FAAH/MGL Inhibitor
FAAH/MAGL-IN-4 is a selective inhibitor of fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL), exhibiting IC50 values of 9.1 nM and 7.9 μM, respectively. This compound plays a critical role in modulating endocannabinoid signaling pathways, making it valuable for investigating pain mechanisms and central nervous system disorders. Its potent inhibitory activity supports research in neurology and pain management applications. -
FAAH/MAGL Inhibitor
Irafamdastat is a potent inhibitor of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), exhibiting IC50 values of ≤ 100 nM for human FAAH and 100 nM-1 µM for human MAGL. This compound has demonstrated antiepileptic effects and is valuable for research into pain management, neuroprotection, and anxiety. Its dual inhibition of FAAH and MAGL positions it as a significant tool for exploring endocannabinoid system modulation in various therapeutic contexts. -
FAAH Inhibitor
FAAH-IN-6 is a potent fatty acid amide hydrolase (FAAH) inhibitor that effectively crosses the blood-brain barrier, exhibiting IC50 values of 0.72 nM and 0.28 nM for human and rat FAAH, respectively. This compound demonstrates significant dose-dependent analgesic effects in preclinical models of neuropathic and inflammatory pain, making it valuable for research on pain management and therapeutic interventions targeting the endocannabinoid system. -
FAAH Inhibitor
N-(3-Methoxybenzyl)Palmitamide is an inhibitor of fatty acid amide hydrolase (FAAH), which is crucial in the regulation of endocannabinoid signaling. This compound exhibits significant anti-inflammatory and analgesic properties, making it a valuable tool for research into pain relief and the treatment of central nervous system degenerative disorders. Its potential applications extend to studying the therapeutic effects of endocannabinoids in various biological contexts. -
FAAH Inhibitor
JNJ-40355003 is a potent and selective fatty acid amide hydrolase (FAAH) inhibitor. It effectively enhances the levels of endocannabinoids, contributing to its biological activity in the modulation of pain, anxiety, and inflammation. This compound is valuable for research in cannabinoid signaling and therapeutic applications targeting the endocannabinoid system. -
FAAH Inhibitor
JP83 is an irreversible inhibitor of fatty acyl amide hydrolase (FAAH), demonstrating an IC50 of 1.6 nM in competitive activity-based protein profiling (ABPP) assays. This compound is valuable for studying the role of FAAH in regulating endocannabinoid signaling and its implications in pain modulation and various neurological disorders. Researchers utilize JP83 to elucidate the mechanistic pathways of FAAH inhibition and explore potential therapeutic applications in cannabinoid pharmacology. -
FAAH Inhibitor
SSR411298 is a selective and reversible inhibitor of fatty acid amide hydrolase (FAAH). This compound demonstrates significant potential in modulating endocannabinoid levels, making it a valuable tool for research related to post-traumatic stress disorder (PTSD) and other neuropsychiatric conditions. Its oral bioavailability further enhances its utility in various preclinical studies. -
FAAH Inhibitor
JP104 is an irreversible inhibitor of fatty acid amide hydrolase (FAAH), exhibiting a potent pIC50 of approximately 8. This compound effectively modulates endocannabinoid levels, making it a valuable tool for studying pain management, neurobiology, and potential therapeutic applications in anxiety and stress-related disorders. Its mechanism of action provides unique insights into the biological pathways influenced by FAAH inhibition. -
FAAH Inhibitor
ASP 8477 is a selective inhibitor of fatty acid amide hydrolase (FAAH), demonstrating IC50 values of 3.99 nM for human FAAH-1, 1.65 nM for the FAAH-1 (P129T) variant, and 57.3 nM for FAAH-2. This compound exhibits central nervous system activity, making it valuable in analgesia research. Its potent inhibition of FAAH positions ASP 8477 as a significant tool for studying pain modulation and endocannabinoid signaling pathways. -
FAAH Inhibitor
PF-622 is a selective inhibitor of fatty acid amide hydrolase (FAAH), which plays a crucial role in the endocannabinoid system. This compound is utilized in research focused on analgesic, anxiolytic, and antidepressant effects, making it valuable for studies exploring pain management and mood disorders. Its ability to modulate endocannabinoid levels enables investigation into therapeutic strategies for various neurological conditions. -
FAAH/MAGL Inhibitor
FAAH/MAGL-IN-3 is an irreversible inhibitor targeting fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) with IC50 values of 179 nM and 759 nM, respectively. This dual inhibitor is valuable for studying endocannabinoid metabolism and its implications in various physiological and pathological processes. Notably, FAAH/MAGL-IN-3 demonstrates low permeability in the PAMPA assay, indicating a potential for selective activity in research applications. -
FAAH Inhibitor
3-Decyl-5,5'-diphenyl-2-thioxo-4-imidazolidinone is a potent inhibitor of fatty acid amide hydrolase (FAAH) with a pI50 of 5.89. This compound exhibits significant activity against endocannabinoids and lipid mediators, making it relevant for studies in pain management, inflammation, and cannabinoid signaling pathways. Its limited affinity for cannabinoid receptors CB(1) and CB(2) allows for targeted research into FAAH-related physiological processes without direct receptor modulation. -
FAAH/cPLA2α Inhibitor
FAAH/cPLA2α-IN-1 is a dual inhibitor targeting fatty acid amide hydrolase (FAAH) and cytosolic phospholipase A2 alpha (cPLA2α), exhibiting IC50 values of 32 nM and 47 nM, respectively. This compound demonstrates potential anti-inflammatory properties by modulating lipid signaling pathways, making it valuable for research into pain management, neuroprotection, and inflammatory responses. Its use in various preclinical studies may provide insights into the therapeutic potential of FAAH and cPLA2α inhibition. -
FAAH Inhibitor
SA57 is a selective inhibitor of fatty acid amide hydrolase (FAAH), exhibiting IC50 values of 3.2 nM and 1.9 nM for mouse and human FAAH, respectively. In addition to its primary target, SA57 demonstrates inhibitory effects on 2-arachidonoylglycerol hydrolases, including monoacylglycerol lipase (MAGL) with IC50s of 410 nM and 1.4 μM for mouse and human, as well as mouse α/β-hydrolase domain-containing protein 6 (mABHD6) with an IC50 of 850 nM. This compound is valuable for research related to the endocannabinoid system and pain management studies. -
FAAH/MAGL Inhibitor
FAAH/MAGL-IN-2 is a potent, reversible inhibitor of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL). It exhibits IC50 values of 11 nM and 36 nM for FAAH and MAGL, respectively, demonstrating significant inhibitory potency. This compound effectively crosses the blood-brain barrier, making it a valuable tool for investigating the role of endogenous lipids in neuropathic pain while minimizing locomotion impairment. Its selective inhibition profile facilitates research into therapeutic approaches for pain management and related disorders. -
FAAH Inhibitor
FAAH-IN-7 is a potent and reversible inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 8.29 nM. This compound effectively reduces oxidative stress in 1321N1 astrocytes and demonstrates significant neuroprotective effects in ex vivo models of neuroinflammation. FAAH-IN-7 is valuable for studies involving neuroprotection and modulation of the endocannabinoid system in various neurological research applications. -
FAAH Inhibitor
URB532 is a selective inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 396 nM. This compound effectively elevates the levels of key endogenous lipid mediators, including arachidonic acid acetamide (AEA), palmitoylethanolamide (PEA), and oleamide (OEA) in the rat brain. URB532 has demonstrated notable anxiolytic and analgesic effects, making it a valuable tool for research on pain and anxiety modulation. -
FAAH Inhibitor
FAAH-IN-5 is an irreversible inhibitor of fatty acid amide hydrolase (FAAH) with a reported IC50 of 10.5 nM, demonstrating relative selectivity. This compound is suitable for research applications focused on endocannabinoid signaling pathways and pain modulation. Despite its potency, FAAH-IN-5 exhibits low permeability in the Parallel Artificial Membrane Permeability Assay (PAMPA), making it an important tool for studies in pharmacokinetics and bioavailability. -
FAAH Inhibitor
URB694 is a carbamate inhibitor of fatty acid amide hydrolase (FAAH) that irreversibly carbamoylates the catalytic serine residue in the FAAH active site. This compound exhibits notable antidepressant-like effects and offers potential cardioprotective properties. URB694 can also be utilized in the synthesis of 11C-Carbonyl-URB694, facilitating in vivo positron emission tomography (PET) imaging studies aimed at elucidating FAAH activity in the brain. -
FAAH Inhibitor
MK-4409 is a potent inhibitor of fatty acid amide hydrolase (FAAH) that demonstrates significant anti-inflammatory properties. It is primarily utilized in research focusing on inflammatory and neuropathic pain mechanisms. The compound’s ability to modulate endocannabinoid levels makes it a valuable tool for studying pain pathways and potential therapeutic interventions. -
FAAH Inhibitor
OL-135 is a selective and reversible inhibitor of fatty acid amide hydrolase (FAAH) that effectively penetrates the central nervous system. It demonstrates notable analgesic properties, making it a valuable tool for research into pain modulation and the endocannabinoid system. This compound is suitable for studies exploring the therapeutic potential of FAAH inhibition in various neurological disorders.
